Transactions
November 21 2012
KippsDeSanto & Co. Advises Emergint Technologies, Inc. on its Sale to CACI International Inc.
KippsDeSanto & Co. is pleased to send you the attached press release announcing the acquisition of our client, Emergint Technologies, Inc. (“Emergint”), by CACI International Inc. (“CACI”). The acquisition of Emergint will enable CACI to expand its capabilities in the rapidly growing healthcare information technology (“HIT”) services market and grow CACI’s footprint at key federal health organizations, primarily the Department of Health and Human Services (“HHS”) and specifically the Centers for Disease Control and Prevention (“CDC”). Emergint represents a public health services provider with exceptional technical capabilities, domain expertise, customer relationships, and intellectual property.
Headquartered in Louisville, KY with offices in Atlanta, GA and Rockville, MD, Emergint is a leading designer, developer, and integrator of systems that ingest, store, analyze, and disseminate complex data sets from disparate systems. The Company also provides full lifecycle systems development and an array of HIT consulting and support services. The Company’s founding vision and enduring core competency is to integrate large amounts of data from disparate systems to enable more meaningful use and application of the information. Emergint has proven past performance and technical and domain expertise in integrating and improving data, ensuring interoperability, and enhancing business intelligence. The Company supports priority programs, such as systems for bioterrorism surveillance and alerting, public health situational awareness, and measurement of healthcare effectiveness.
Emergint has an established footprint across various elements of HHS. It is one of the most active contractors at CDC with strategic relationships across multiple organizations, including the Office of Surveillance Epidemiology and Laboratory Services, Division of Health and Quality Promotion’s National Health Safety Network, and Office of Infectious Diseases. The Company has a deep organizational knowledge of CDC’s systems, operations, and requirements that afford it the ability to continue to deliver superior solutions, anticipate future requirements, and differentiate itself within that marketplace. Emergint is also well positioned to expand in adjacent customer communities including the National Institutes of Health (“NIH”), Environmental Protection Agency (“EPA”), Food and Drug Administration (“FDA”), and broader parts of HHS.
We believe this transaction demonstrates several key trends in the government technology M&A environment:
• Strong buyer appetite for companies well-positioned with mission-oriented customers, and oriented toward those market segments anticipating strong future growth, such as health IT, big data, and cyber and intelligence.
• Strategic buyers continue to target M&A opportunities that address strategic gaps or augment an existing presence with substantive depth in those priority areas.
• Given macro-economic and federal budget uncertainty, buyers seek targets with sustainable growth potential evidenced by actionable new business opportunities.
• Targets operating at the front-end of contracts (with significant backlog) that provide strong revenue visibility and organic growth potential are highly sought after.
KippsDeSanto & Co. is an investment bank focused on delivering exceptional M&A and financing transaction results for leading technology and defense companies. For more information on KippsDeSanto & Co., please visit www.kippsdesanto.com.
We welcome the opportunity to discuss how KippsDeSanto & Co. can help you achieve your strategic objectives.
KippsDeSanto & Co., member FINRA/SIPC, is not affiliated with other companies mentioned herein
LEAD INVESTMENT BANKERS
Bob Kipps
Marc B. Marlin
KippsDeSanto & Co. is pleased to send you the attached press release announcing the acquisition of our client, Emergint Technologies, Inc. (“Emergint”), by CACI International Inc. (“CACI”). The acquisition of Emergint will enable CACI to expand its capabilities in the rapidly growing healthcare information technology (“HIT”) services market and grow CACI’s footprint at key federal health organizations, primarily the Department of Health and Human Services (“HHS”) and specifically the Centers for Disease Control and Prevention (“CDC”). Emergint represents a public health services provider with exceptional technical capabilities, domain expertise, customer relationships, and intellectual property.
Headquartered in Louisville, KY with offices in Atlanta, GA and Rockville, MD, Emergint is a leading designer, developer, and integrator of systems that ingest, store, analyze, and disseminate complex data sets from disparate systems. The Company also provides full lifecycle systems development and an array of HIT consulting and support services. The Company’s founding vision and enduring core competency is to integrate large amounts of data from disparate systems to enable more meaningful use and application of the information. Emergint has proven past performance and technical and domain expertise in integrating and improving data, ensuring interoperability, and enhancing business intelligence. The Company supports priority programs, such as systems for bioterrorism surveillance and alerting, public health situational awareness, and measurement of healthcare effectiveness.
Emergint has an established footprint across various elements of HHS. It is one of the most active contractors at CDC with strategic relationships across multiple organizations, including the Office of Surveillance Epidemiology and Laboratory Services, Division of Health and Quality Promotion’s National Health Safety Network, and Office of Infectious Diseases. The Company has a deep organizational knowledge of CDC’s systems, operations, and requirements that afford it the ability to continue to deliver superior solutions, anticipate future requirements, and differentiate itself within that marketplace. Emergint is also well positioned to expand in adjacent customer communities including the National Institutes of Health (“NIH”), Environmental Protection Agency (“EPA”), Food and Drug Administration (“FDA”), and broader parts of HHS.
We believe this transaction demonstrates several key trends in the government technology M&A environment:
• Strong buyer appetite for companies well-positioned with mission-oriented customers, and oriented toward those market segments anticipating strong future growth, such as health IT, big data, and cyber and intelligence.
• Strategic buyers continue to target M&A opportunities that address strategic gaps or augment an existing presence with substantive depth in those priority areas.
• Given macro-economic and federal budget uncertainty, buyers seek targets with sustainable growth potential evidenced by actionable new business opportunities.
• Targets operating at the front-end of contracts (with significant backlog) that provide strong revenue visibility and organic growth potential are highly sought after.
KippsDeSanto & Co. is an investment bank focused on delivering exceptional M&A and financing transaction results for leading technology and defense companies. For more information on KippsDeSanto & Co., please visit www.kippsdesanto.com.
We welcome the opportunity to discuss how KippsDeSanto & Co. can help you achieve your strategic objectives.
KippsDeSanto & Co., member FINRA/SIPC, is not affiliated with other companies mentioned herein
LEAD INVESTMENT BANKERS
Bob Kipps
Marc B. Marlin
We prioritize your privacy. We do not sell your information and will only send occasional, relevant emails.
Copyright © 2025 KippsDeSanto & Co.
All Rights Reserved